Case Report
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Nov 6, 2023; 11(31): 7629-7634
Published online Nov 6, 2023. doi: 10.12998/wjcc.v11.i31.7629
Sunitinib-induced hyperammonemic encephalopathy in metastatic gastrointestinal stromal tumors: A case report
Takaoki Hayakawa, Shinsuke Funakoshi, Yasuo Hamamoto, Kenro Hirata, Takanori Kanai
Takaoki Hayakawa, Department of Internal Medicine, Division of Gastroenterology and Hepatology, Keio University School of Medicine, Shinjuku-ku 160-8582, Tokyo, Japan
Shinsuke Funakoshi, Division of Medical Oncology, Department of Internal Medicine, Tokyo Saiseikai Central Hospital, Minato-ku 108-0073, Tokyo, Japan
Yasuo Hamamoto, Kenro Hirata, Keio Cancer Center, Keio University School of Medicine, Shinjuku-ku 160-8582, Tokyo, Japan
Takanori Kanai, Department of Internal Medicine, Keio University School of Medicine, Shinjuku-ku 160-8582, Tokyo, Japan
Author contributions: Hayakawa T obtained all the required data and drafted the article after a literature review; Hamamoto Y, Funakoshi S and Hirata K, a medical oncologist, revised the article; and Kanai T, a medical gastroenterologist, critically revised the article and approved its final version.
Informed consent statement: Written informed consent was obtained from the patient for the publication of this article and any accompanying images.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Yasuo Hamamoto, MD, PhD, Assistant Professor, Doctor, Keio Cancer Center, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku 160-8582, Tokyo, Japan. yashmmt1971@gmail.com
Received: June 29, 2023
Peer-review started: June 29, 2023
First decision: September 26, 2023
Revised: October 10, 2023
Accepted: October 23, 2023
Article in press: October 23, 2023
Published online: November 6, 2023
Core Tip

Core Tip: This case is distinctive because the patient was diagnosed with a rare hyperammonemic encephalopathy caused by sunitinib, which was administered as treatment for gastrointestinal stromal tumors. We emphasize the need for systemic evaluation and prompt action for patients receiving tyrosine kinase inhibitors who present with adverse effects.